Korean Market
EXCH
Yuhan
★

Yuhan Corporation Publishes Corporate Governance Report: Strengthened Shareholder Return Policy with Share Buyback/Cancellation and Dividend Increase Under Public Foundation Majority Ownership

 
OWNR
Yuhan
★

Yuhan Non-Registered Executive Lee Byung-man Increases Stake by 200 Shares via Open Market Purchase

 
OWNR
Yuhan
★

Yuhan Non-Registered Executive Yun Dong-su Acquires 100 Additional Shares via Open Market Purchase... Negligible Ownership Change, Minimal Impact on Shareholder Value

 
EXCH
Yuhan
★

Notice of 2026 R&D Day

 
EXCH
Yuhan
★

Signed 210.2 Billion KRW API Supply Contract with Gilead (9.6% of Sales)

 
OWNR
Yuhan
★

Insider Ownership Report with No Change in Stake

 
OWNR
Yuhan
★

No Change in Specific Securities Ownership Report

 
OWNR
Yuhan
★

Submission of Insider Ownership Report

 
EXCH
Yuhan
★

Q1 2026 Business Results IR Meeting

 
PERI
Yuhan
★★★★

Yuhan Corporation Q1 2026: Revenue up 7.2%, Operating Profit up 37.3% – Lazertinib Global Approvals and Enhanced Shareholder Returns via Treasury Share Cancellation

 
EXCH
Yuhan
★★★★

Lazertinib European Commercialization Milestone Achieved, $30M Payment Received

 
EXCH
Yuhan
★

ImmuneOncia Rights Offering Finalized at 4,860 Won, Operating Funds Adjusted to 81.8B Won

 
OWNR
Yuhan
★

Simplified Large Shareholding Report Template - No Specific Data

 
OWNR
Yuhan
★

Filing of Officer/Major Shareholder Securities Ownership Report

 
OWNR
Yuhan
★

Insider Shareholding Report Filed (No Changes)